• Maria Cecilia Mengoli, Fausto Barbieri, Federica Bertolini, Marcello Tiseo, and Giulio Rossi.
• Unit of Pathology, University Hospital Policlinico, Modena, Italy. Electronic address: cecilia.mengoli@gmail.com.
• Lung Cancer. 2016 Mar 1; 93: 55-8.

AbstractThe paradigm of mutually exclusive alterations among oncogenic drivers in non-small-cell lung cancer (NSCLC) is challenged by the increasing evidence of detection of two or more driver alterations in the same tumor using highly-sensitive molecular assays. We report here two cases of ALK-rearranged adenocarcinomas harboring concomitant exon 2 K-RAS mutations (G13D and Q61H). The patients, a 49-year-old smoker man and a 59-year-old non-smoking woman, experienced a rapid disease progression and primary resistance to crizotinib. Search for similar cases in the literature reveals that concomitant K-RAS mutations and ALK rearrangement occur in a subset of NSCLC and seems to lead to resistance to crizotinib. Among 8 similar cases receiving crizotinib previously reported (4 in first line and 4 in second line), 1 had a partial response, 1 stable disease and 6 disease progression. One patient still had progression disease when switching to ceritinib. At the end, K-RAS mutations seem to represent a negative predictive marker in ALK-rearranged adenocarcinomas treated with ALK inhibitor.Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

47 keywords...

hide…